Finance

European stocks rise as earnings season opens; Novo Nordisk looms

European markets are poised for a broadly positive open as earnings season kicks off, with CAC 40 up about 0.24% and DAX showing modest gains while FTSE 100 sits near flat. Novo Nordisk and a slate of big-name results will set the tone for risk appetite in the sector.

📅 February 04, 2026
⏱️ 2 min read
European stocks rise as earnings season opens; Novo Nordisk looms

Key Takeaways

  • CAC 40 is up about 0.24% while other major Euro indices edge higher or hold flat
  • Earnings season begins with reports from Novartis, Santander, GSK, Infineon, Equinor, Credit Agricole, Handelsbanken, Carlsberg and OMV
  • Novo Nordisk is in focus amid quarterly results and ongoing Wegovy/Ozempic exclusivity and US price-pressure concerns
  • Gold and cryptocurrencies stabilize or drift lower pre-open as US stock futures stay near flat

People Involved

  • No specific individuals mentioned

Entities Involved

  • Novo NordiskPharmaceuticals company; key bellwether for healthcare given Wegovy/Ozempic dynamics and exclusivity concerns in several markets
  • UBSInvestment bank; Q4 results beat expectations (per reports)
  • NovartisPharmaceuticals company
  • Banco SantanderBanking group
  • GSKPharmaceuticals/consumer health company
  • Infineon TechnologiesSemiconductors company
  • EquinorEnergy company (oil and gas)
  • Credit AgricoleFrench bank
  • HandelsbankenSwedish bank
  • CarlsbergDanish brewer
  • OMVAustrian oil & gas company

MarketMoodz Analysis

A stronger start to European earnings can lift risk sentiment for global portfolios, potentially pushing European equities higher and supporting a softer dollar if EUR/USD strengthens on improved risk appetite. The focus on Novo Nordisk underscores how US price dynamics and exclusivity status for high-demand therapies can ripple through global equity markets, given the company’s sizable exposure to US pricing trends.

Historically, a positive European open can seed momentum for U.S.-listed peers and global funds, with cross-asset moves in equities, bonds, gold and crypto reacting to guidance from earnings and central bank commentary. Investors should watch next for detailed earnings guidance from the reported companies, any shifts in European rate expectations, and updates on commodity prices and energy names that could influence hedging and allocation strategies.

What to watch next: watch Novo Nordisk’s guidance and region-specific exclusivity developments; monitor UBS’s official Q4 results and its outlook; track how European banks and energy names frame the macro environment and potential shifts in credit conditions. Also observe EUR/USD moves, gold, and crypto prices as they often lead risk-on/risk-off shifts.

Source: Original Article

Get AI-Powered Market Insights

Stay ahead of market-moving events with our real-time analysis and stock ratings.

Start Your Free Trial